Gubra (GUBRA) Stock Overview

Gubra A/S operates as a biotech company with two primary areas of business: pre-clinical contract research (CRO) services and proprietary early target and drug discovery programs. The CRO segment offers pre-clinical contract research and development services for the pharmaceutical and biotechnology industry, as well as provides services in vivo pharmacology, tissue research, assays, molecular pharmacology, bioanalysis, sequencing (NGS), and 2D and 3D imaging. The company has a research and license agreement with Boehringer Ingelheim to discover novel peptides for the treatment of obesity. The company was incorporated in 2008 and is based in Horsholm, Denmark.